[PARIS] French prescribed drugs big Sanofi stated on Wednesday (Feb 23) that its Covid-19 vaccine, developed with Britain’s GSK, had delivered optimistic outcomes after almost a 12 months of delays left it lagging far behind rivals within the race for a jab.
The 2 drugmakers stated in a press release they may “search regulatory authorisation” for his or her vaccine in the US and the European Union following part 3 trials involving hundreds of individuals.
The trials – which haven’t but been launched – indicated that the vaccine was 100 per cent efficient in opposition to extreme Covid illness and hospitalisations, Sanofi stated.
It was additionally greater than 50 per cent efficient in opposition to all symptomatic Covid, it added.
The outcomes put the jab “in keeping with anticipated vaccine effectiveness in right this moment’s atmosphere dominated by variants of concern”, comparable to Omicron.
If the vaccine receives authorisation, it’ll mark the tip of Sanofi’s lengthy battle to develop a Covid vaccine following quite a few setbacks and delays.
The French agency had initially hoped to make a vaccine obtainable by mid-2021.
However the date was pushed again by six months because of a dosing error, then was once more delayed after difficulties discovering uninfected folks to take the trials.
Sanofi additionally deserted a earlier vaccine venture primarily based on the mRNA know-how utilized by its rivals Pfizer/BioNTech and Moderna, which have shaped the spine of vaccination efforts in lots of Western nations.
It’s now targeted on a vaccine utilizing a barely much less modern approach primarily based on recombinant protein know-how, additionally seen within the Novavax jab. AFP